Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Use  



1.1  In humans  





1.2  In horses  







2 References  














Isoxsuprine






العربية
Cymraeg
فارسی
Italiano
Српски / srpski
Srpskohrvatski / српскохрватски
Українська
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Isoxsuprine
Clinical data
Pronunciation/ˈsɒksjʊprn/
Trade namesDuvadilan, Vasodilan
MedlinePlusa682831
Routes of
administration
Oral (tablets)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~100% (humans),[1] 2.2% (horses; oral)[2]
Onset of action1 hour
Elimination half-life<3 hours (horses)[3]
ExcretionMainly renal
Identifiers
  • 4-{1-Hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol

CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.272 Edit this at Wikidata
Chemical and physical data
FormulaC18H23NO3
Molar mass301.386 g·mol−1
3D model (JSmol)
  • O(c1ccccc1)CC(NC(C)C(O)c2ccc(O)cc2)C

  • InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3 checkY

  • Key:BMUKKTUHUDJSNZ-UHFFFAOYSA-N checkY

Isoxsuprine (used as isoxsuprine hydrochloride) is a drug used as a vasodilator[4]inhumans (under the trade name Duvadilan) and equines. Isoxsuprine is a β2 adrenoreceptor agonist that causes direct relaxation of uterine and vascular smooth muscle via β2 receptors.[5]

Use[edit]

In humans[edit]

Isoxsuprine is used in humans for treatment of premature labor, i.e. a tocolytic,[6] and as a vasodilator for the treatment of cerebral vascular insufficiency, Raynaud's phenomenon, and other conditions.[7]

Isoxsuprine may increase the heart rate, cause changes in blood pressure, and irritate the GI tract. It should therefore be used with caution if combined with other drugs that affect blood pressure, such as sedatives and anesthetic drugs.

In horses[edit]

Isoxsuprine is most commonly used to treat hoof-related problems in the horse, most commonly for laminitis and navicular disease, as its effects as a vasodilator are thought to increase circulation within the hoof to help counteract the problems associated with these conditions. Isoxsuprine is given orally, and many horses find the pills quite palatable.[8] Isoxsuprine is a prohibited class B drug in FEI-regulated competition, and is often prohibited by other equine associations. It may be detected in the urine for several weeks or months following administration. It is therefore important to check the drug-rules within an animal's given competitive organization, before administering the drug.

Because it is a vasodilator, it should not be used in horses that are bleeding, or in mares following foaling.

References[edit]

  1. ^ McGuigan MA, Whyte IM, Dawson AH, Seifert SA, Schonwald S, Yip L, et al. (2004). "125. Vasodilators". In Dart RC (ed.). Medical Toxicology (3rd ed.). Philadelphia [u.a.]: Lippincott Williams & Wilkins. p. 718. ISBN 978-0781728454.
  • ^ Erkert RS, Macallister CG (April 2002). "Isoxsuprine hydrochloride in the horse: a review". Journal of Veterinary Pharmacology and Therapeutics. 25 (2): 81–87. doi:10.1046/j.1365-2885.2002.00386.x. PMID 12000527.
  • ^ Cole C, Bentz B, Maxwell L, eds. (2014). "13. Clinical pharmacology of the equine musculoskeletal system". Equine Pharmacology. Wiley—Blackwell. p. 224. ISBN 978-0-8138-2262-4.
  • ^ Gozo EG, Yebes RB (November 1984). "Hemodynamic effects of isoxsuprine in cardiac failure". Chest. 86 (5): 736–40. doi:10.1378/chest.86.5.736. PMID 6488912.
  • ^ Falkay G, Kovács L (1986). "Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors". Journal of Perinatal Medicine. 14 (2): 109–13. doi:10.1515/jpme.1986.14.2.109. PMID 2874205. S2CID 6039919.
  • ^ Giorgino FL, Egan CG (2010). "Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature". Arzneimittel-Forschung. 60 (7): 415–20. doi:10.1055/s-0031-1296305. PMID 20712130. S2CID 21297911.
  • ^ "Isoxsuprine". Drugs.com.
  • ^ Forney BC (2007). Equine Medications. The Horse health care library. Lexington, KY: Eclipse Press. OCLC 1360077554.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Isoxsuprine&oldid=1191984982"

    Categories: 
    Secondary alcohols
    Amines
    Beta-adrenergic agonists
    Equine medications
    NMDA receptor antagonists
    Phenol ethers
    Phenols
    Phenylethanolamines
    Vasodilators
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Drugs with non-standard legal status
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Articles containing unverified chemical infoboxes
     



    This page was last edited on 26 December 2023, at 23:54 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki